Novo heralds promising PhIII diabetes data for once-weekly semaglutide

John Carroll Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug–a key ...

UPDATED: Biogen R&D chief Doug Williams joins exodus to run a biotech upstart

John Carroll Biogen's high-profile R&D chief, Doug Williams, has heard the siren song of a biotech startup. Near midday on Friday, the Big Biotech put out word that Williams ...

Novartis’ pay-for-performance Entresto plan has its critics–Express Scripts’ Miller among them

Carly Helfand Novartis has said it's planning to offer an outcomes-based plan for its new blockbuster-in-the-making to secure payers' favor. But skeptics see some kinks in the ...

FierceBiotech Radio on big approvals for Novartis and Vertex, Mylan’s real estate controversy, and @brentlsaunders

Alok Saboo FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss the week's biggest news in biopharma, including Novartis and Vertex Pharmaceuticals scoring ...

Maryland Rep joins chorus of Amphastar critics, urging OD drug price deal

Tracy Staton Amphastar is in hot water with U.S. officials again. After New York and other states put the squeeze on the company to drop the price of its overdose drug, naloxone, Rep. ...

You want a formal offer, Mylan? Teva could have one this week

Carly Helfand Last month, Mylan Chairman Robert Coury challenged suitor Teva to either put up a formal bid or step aside and let his company proceed with its plan to pursue its own ...

Novo Nordisk backs out of a diabetes deal with Zosano

Damian Garde Novo Nordisk has terminated a collaboration deal with Zosano Pharma, walking away from an agreement that would have paired its late-stage diabetes drug with the latter ...

Gilead takes a $125M FDA shortcut with its latest HIV combo

Damian Garde Last year, Gilead Sciences paid $ 125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment ...

Eylea expected to keep delivering for Regeneron as Praluent starts to step up

Carly Helfand Eye blockbuster Eylea has been churning out serious revenue growth for Regeneron since it hit the market, and now the company is inching closer to approval for its much-watched ...

Scientists dig up new evidence linking GSK’s Pandemrix with narcolepsy

Tracy Staton A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's now-withdrawn flu shot Pandemrix was associated with a spike ...

Ex-Pharmacyclics team raises $33.5M for checkpoint drug

John Carroll Ex-Pharmacyclics CEO Richard Miller is looking for a second act in biotech with his startup Corvus Pharmaceuticals. FierceBiotech News

Boehringer gets respiratory boost with batch of Spiolto nods in EU

Carly Helfand When Boehringer Ingelheim's COPD drug Stiolto Respimat won U.S. approval early last month, the company's head of pharma marketing and sales, Allan Hillgrove, acknowledged ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS